Survival-Associated Alternative Splicing Events and Prognostic Signatures in Pancreatic Cancer

Overview

Journal Front Genet

Date 2020 Nov 16

PMID 33193606

Citations 4

Authors

Lichao Xu

Jingxin Pan

Yanni Ding

Hongda Pan

Affiliations

Soon will be listed here.

Abstract

Background: Alternative splicing (AS) is reported to be related to the biological process of multiple malignancies. This study is conducted to identify survival-associated AS events and prognostic signatures that may serve as prognostic indicators for pancreatic cancer (PC).

Methods: Univariate Cox analysis was used to determine the survival-associated AS events in PC. Prognostic signatures were constructed by LASSO Cox analysis based on seven types of survival-associated AS events. The correlation between the expression of splicing factors (SFs) and the percent spliced in values of AS events was analyzed by Pearson correlation analysis. Risk scores were calculated to determine high- or low-risk patients with different types of AS events. Gene functional annotation analysis was performed to reveal pathways in which prognostic AS is enriched.

Results: A total of 45,313 AS events in 10,624 genes were observed, and there were 1,565 AS events in 1,223 genes significantly correlated with overall survival for PC. Kaplan-Meier analysis, receiver-operator characteristic curve, univariate and multivariate Cox analyses showed that AS prognostic signatures could effectively predict prognosis of patients with PC. Splicing factors-AS regulatory networks were established to demonstrate the interaction between AS events and SFs.

Conclusion: The survival-associated AS events and prognostic signatures identified in this study can serve as useful tool for predicting prognosis of patients with PC. Moreover, the SF-AS regulatory networks may provide clues for the mechanisms underlying AS in PC.

Citing Articles

A glycosylation-related signature predicts survival in pancreatic cancer.

Hu H, He B, He M, Tao H, Li B Aging (Albany NY). 2023; 15(23):13710-13737.

PMID: 38048216 PMC: 10756102. DOI: 10.18632/aging.205258.

Identification of alternative splicing associated with clinical features: from pan-cancers to genitourinary tumors.

Duan C, Zhang Y, Li L, Liu K, Yao X, Wu X Front Oncol. 2023; 13:1249932.

PMID: 37810965 PMC: 10557043. DOI: 10.3389/fonc.2023.1249932.

Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.

Sahin I, George A, Seyhan A Int J Mol Sci. 2021; 22(21).

PMID: 34769221 PMC: 8583749. DOI: 10.3390/ijms222111790.

Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update.

Matiash K, Lewis C, Bogdanov V Cancers (Basel). 2021; 13(18).

PMID: 34572880 PMC: 8471299. DOI: 10.3390/cancers13184652.

References

Zhang J, Chang C, Lombardi L, Dalla-Favera R . Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene. 1994; 9(7):1931-7. View

Kariri Y, Joseph C, Kurozumi S, Toss M, Alsaleem M, Raafat S . Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. Breast Cancer Res Treat. 2019; 179(2):349-357. PMC: 6987050. DOI: 10.1007/s10549-019-05466-8. View

Chen Q, Li W, Wu P, Shen L, Huang Z . Alternative splicing events are prognostic in hepatocellular carcinoma. Aging (Albany NY). 2019; 11(13):4720-4735. PMC: 6660027. DOI: 10.18632/aging.102085. View

Ludlow A, Wong M, Robin J, Batten K, Yuan L, Lai T . NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun. 2018; 9(1):3112. PMC: 6079032. DOI: 10.1038/s41467-018-05582-x. View

Sveen A, Kilpinen S, Ruusulehto A, Lothe R, Skotheim R . Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2015; 35(19):2413-27. DOI: 10.1038/onc.2015.318. View

Piva F, Giulietti M, Burini A, Principato G . SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 2011; 33(1):81-5. DOI: 10.1002/humu.21609. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Mao S, Li Y, Lu Z, Che Y, Sun S, Huang J . Survival-associated alternative splicing signatures in esophageal carcinoma. Carcinogenesis. 2018; 40(1):121-130. DOI: 10.1093/carcin/bgy123. View

Huang Z, He R, Mo Z . Prognostic value and potential function of splicing events in prostate adenocarcinoma. Int J Oncol. 2018; 53(6):2473-2487. PMC: 6203144. DOI: 10.3892/ijo.2018.4563. View

10.

Engebretsen S, Bohlin J . Statistical predictions with glmnet. Clin Epigenetics. 2019; 11(1):123. PMC: 6708235. DOI: 10.1186/s13148-019-0730-1. View

11.

Lin P, He R, Ma F, Liang L, He Y, Yang H . Systematic Analysis of Survival-Associated Alternative Splicing Signatures in Gastrointestinal Pan-Adenocarcinomas. EBioMedicine. 2018; 34:46-60. PMC: 6116578. DOI: 10.1016/j.ebiom.2018.07.040. View

12.

Zhu G, Zhou Y, Qiu L, Wang B, Yang Y, Liao W . Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. Carcinogenesis. 2019; 40(9):1077-1085. DOI: 10.1093/carcin/bgz073. View

13.

Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E . The Functional Impact of Alternative Splicing in Cancer. Cell Rep. 2017; 20(9):2215-2226. DOI: 10.1016/j.celrep.2017.08.012. View

14.

Neoptolemos J, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer D . Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018; 15(6):333-348. DOI: 10.1038/s41575-018-0005-x. View

15.

He L, Yuan L, Sun Y, Wang P, Zhang H, Feng X . Glucocorticoid Receptor Signaling Activates TEAD4 to Promote Breast Cancer Progression. Cancer Res. 2019; 79(17):4399-4411. DOI: 10.1158/0008-5472.CAN-19-0012. View

16.

Conway J, Lex A, Gehlenborg N . UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017; 33(18):2938-2940. PMC: 5870712. DOI: 10.1093/bioinformatics/btx364. View

17.

Wong A, Rasko J, Wong J . We skip to work: alternative splicing in normal and malignant myelopoiesis. Leukemia. 2018; 32(5):1081-1093. DOI: 10.1038/s41375-018-0021-4. View

18.

Heagerty P, Lumley T, Pepe M . Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2):337-44. DOI: 10.1111/j.0006-341x.2000.00337.x. View

19.

Zhang Y, Yan L, Zeng J, Zhou H, Liu H, Yu G . Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers. Oncogene. 2019; 38(40):6678-6695. DOI: 10.1038/s41388-019-0910-7. View

20.

Lleres D, Moindrot B, Pathak R, Piras V, Matelot M, Pignard B . CTCF modulates allele-specific sub-TAD organization and imprinted gene activity at the mouse Dlk1-Dio3 and Igf2-H19 domains. Genome Biol. 2019; 20(1):272. PMC: 6909504. DOI: 10.1186/s13059-019-1896-8. View